Waycross Partners LLC Purchases Shares of 5,732 Gilead Sciences, Inc. $GILD

Key Points

• Waycross Partners LLC purchased 5,732 shares of Gilead Sciences, Inc. valued at approximately $636,000 during the second quarter, as revealed in a recent SEC filing.
• Gilead Sciences reported a quarterly earnings of $2.01 EPS, exceeding analyst estimates, with a revenue of $7.08 billion for the quarter.
• The company announced a quarterly dividend of $0.79 per share, representing an annualized dividend yield of 2.8%, with a payout ratio of 62.95%.

Waycross Partners LLC purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 5,732 shares of the biopharmaceutical company's stock, valued at approximately $636,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Covea Finance raised its stake in Gilead Sciences by 69.5% in the second quarter. Covea Finance now owns 51,700 shares of the biopharmaceutical company's stock valued at $5,732,000 after buying an additional 21,200 shares in the last quarter. CGN Advisors LLC raised its stake in Gilead Sciences by 1.4% in the second quarter. CGN Advisors LLC now owns 26,544 shares of the biopharmaceutical company's stock valued at $2,943,000 after buying an additional 373 shares in the last quarter. Occidental Asset Management LLC raised its stake in Gilead Sciences by 1.4% in the second quarter. Occidental Asset Management LLC now owns 40,670 shares of the biopharmaceutical company's stock valued at $4,509,000 after buying an additional 551 shares in the last quarter. CHICAGO TRUST Co NA raised its stake in Gilead Sciences by 25.9% in the second quarter. CHICAGO TRUST Co NA now owns 2,900 shares of the biopharmaceutical company's stock valued at $322,000 after buying an additional 597 shares in the last quarter. Finally, Oliver Luxxe Assets LLC increased its position in shares of Gilead Sciences by 5.3% during the second quarter. Oliver Luxxe Assets LLC now owns 62,465 shares of the biopharmaceutical company's stock worth $6,925,000 after purchasing an additional 3,156 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Shares of GILD opened at $114.40 on Wednesday. Gilead Sciences, Inc. has a twelve month low of $81.83 and a twelve month high of $121.83. The stock's 50 day moving average is $114.21 and its two-hundred day moving average is $109.98. The firm has a market capitalization of $141.95 billion, a PE ratio of 22.79, a P/E/G ratio of 0.76 and a beta of 0.36. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the previous year, the company earned $2.01 EPS. The company's quarterly revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be given a $0.79 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. Gilead Sciences's dividend payout ratio (DPR) is currently 62.95%.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the transaction, the insider owned 114,168 shares in the company, valued at $13,532,333.04. This trade represents a 19.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $296,325.00. Following the completion of the transaction, the chief financial officer owned 160,110 shares of the company's stock, valued at approximately $18,977,838.30. This represents a 1.54% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 82,000 shares of company stock worth $9,390,030. Corporate insiders own 0.27% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Royal Bank Of Canada lifted their target price on Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research report on Friday, August 8th. Rothschild & Co Redburn lifted their target price on Gilead Sciences from $136.00 to $143.00 and gave the stock a "buy" rating in a research report on Friday, September 12th. Truist Financial upgraded Gilead Sciences from a "hold" rating to a "buy" rating and lifted their target price for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. UBS Group lifted their target price on Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research report on Friday, August 8th. Finally, Daiwa America upgraded Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $117.17.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.